Epcoritamab-bysp - Biologic Drug Details

Summary for epcoritamab-bysp

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for epcoritamab-bysp

Mechanism of Action	CD20-directed Antibody Interactions CD3 Receptor Agonists CD3-directed Antibody Interactions Cytochrome P450 Inhibitors
Physiological Effect	Increased Cytokine Activity
Established Pharmacologic Class	Bispecific CD20-directed CD3 T Cell Engager

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for epcoritamab-bysp Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for epcoritamab-bysp Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for epcoritamab-bysp Derived from Patent Text Search

No patents found based on company disclosures

Market Dynamics and Financial Trajectory for Epcoritamab-bysp

Last updated: February 24, 2026

Epcoritamab-bysp is a bispecific antibody targeting CD20 and CD3, developed by Genmab and AbbVie. It operates within the B-cell lymphoma treatment segment, driven by increasing prevalence of relapsed or refractory non-Hodgkin lymphoma (NHL) and mantle cell lymphoma (MCL).

Market Overview

Indications and Approved Label

Epcoritamab is primarily indicated for relapsed or refractory B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma (DLBCL) and MCL. It received accelerated approval by the FDA in October 2022 under the 505(b)(2) pathway, based on early-phase clinical data demonstrating significant response rates in heavily pretreated populations.

Competitive Landscape

The targeted lymphoma therapy market includes rituximab, polatuzumab vedotin, CAR-T therapies (e.g., axi-cel, tisa-cel), and other bispecific antibodies. Epcoritamab competes with these agents, particularly CAR-T therapies and other off-the-shelf bispecifics like GEN3013 (teilizumab) and mosunetuzumab.

Market Size and Growth Drivers

• Global NHL market estimate (2022): $17.5 billion (MarketWatch, 2022).
• Projected CAGR (2022–2027): approximately 7.2% (Fortune Business Insights, 2022).
• Epcoritamab's potential penetration: limited initially, with estimates suggesting $500 million to $1 billion in sales within five years post-approval, assuming approval for multiple lines of therapy.

Reimbursement and Pricing Factors

Pricing for similar biologics ranges from $150,000 to $200,000 annually per patient. Reimbursement will depend on payer coverage, with value-based agreements considered given the high cost and novel mechanism.

Clinical Development and Pipeline Progression

Trials and Data

• Phase 1/2 trials showed overall response rates (ORR) up to 80% in specific relapsed/refractory patient populations.
• Complete remission (CR) observed in approximately 40–50% of patients.
• Ongoing Phase 3 trials aim to compare epcoritamab against standard-of-care salvage regimens.

Expansion Potential

• Additional indications: follicular lymphoma, chronic lymphocytic leukemia.
• Combination therapies: trials explore combining epcoritamab with chemo-immunotherapy and novel agents.

Revenue Projections and Financial Trajectory

Year	Estimated Revenue ($ millions)	Key Assumptions
2023	50–100	Limited initial supply, early market adoption
2024	150–300	Expanded indications, payer coverage, broader access
2025	400–600	Adoption in second-line settings, competitive positioning
2026–2027	800–1,200	Data-driven expansion, potential label broadened

Factors Influencing Revenue Trajectory

• Launch speed, geographic expansion, and adoption rate.
• Competitive entry by CAR-T and other bispecifics.
• Reimbursement policies and pricing strategies.

Regulatory and Market Access Outlook

Expectations of regulatory filings in Europe and Japan within 2023–2024. Market access negotiations will influence price points, particularly in high-cost regions.

Key Risks and Challenges

• Competition from established CAR-T therapies and emerging bispecifics.
• Manufacturing complexities affecting supply consistency.
• Payer reimbursement constraints limiting access.

Key Takeaways

Epcoritamab-bysp enters a growing lymphoma market with promising early data. Its commercialization depends on clinical efficacy, competitive positioning, reimbursement landscape, and manufacturing capacity. Sales are projected to scale from tens of millions in 2023 to over a billion dollars by 2027 under optimistic assumptions. Risks include competitive pressure and regulatory hurdles.

FAQs

1. How does epcoritamab differ from other bispecific antibodies?
It targets CD20 and CD3, similar to others like mosunetuzumab, but its specific molecular structure and administration schedule may influence its efficacy and tolerability profile.

2. What are the main competitors for epcoritamab in lymphoma?
CAR-T therapies (axi-cel, tisa-cel), other bispecifics (mosunetuzumab, glofitamab), and antibody-drug conjugates like polatuzumab vedotin.

3. When is regulatory approval expected in major markets?
Accelerated FDA approval was granted in October 2022. European and Asian submissions are expected by 2023–2024.

4. What are the main clinical efficacy benchmarks?
ORR of approximately 80%, CR rates of 40–50% in heavily pretreated relapsed/refractory populations.

5. How might reimbursement challenges impact sales?
High treatment costs could limit access; value-based pricing and reimbursement negotiations will be pivotal.

---

References

1. MarketWatch. (2022). Non-Hodgkin Lymphoma Market Size, Share & Trends.
2. Fortune Business Insights. (2022). Global Lymphoma Therapeutics Market Forecast.
3. U.S. Food and Drug Administration. (2022). Epcioritamab-Bysp Approval Notice.